Indexado en

Licencia y uso

Citaciones

Cited 1 times in

Altmetrics

Grant support

Ramon Bataller is a recipient of NIA AA grants U01AA021908 and U01AA020821 from Instituto de Salud Carlos III (PI24/1984) . Edilmar Alvarado-Tapias is a recipient of a Joan Rodes award from the Instituto de Salud Carlos III (JR20/00047) and the PI21/01995 grant from the Instituto de Salud Carlos III-Fondos Feder. Elisa Pose is a recipient of an Instituto de Salud Carlos III grant PI22/00910. Jordi Gratacos-Gines is supported by a Rio Hortega grant, Instituto de Salud Carlos III-Accion Estrategica en Salud, 2021. Ana Clemente-Sanchez is a recipient of a Joan Rodes award from the Instituto de Salud Carlos III (JR23/00080) . Hugo Lopez-Pelayo is a recipient of Red de Investigacion en Atencion Primaria de Adicciones, (RIAPAd (RICORS) ) , which is a project (RD21/0009/0010) funded by the Carlos III Institute, the European Regional Development Fund, and the Recovery, Transformation, and Resilience Plan.r gica en Salud, 2021. Ana Clemente-Sanchez is a recipient of a Joan Rodes award from the Instituto de Salud Carlos III (JR23/00080) . Hugo Lopez-Pelayo is a recipient of Red de Investigacion en Atencion Primaria de Adicciones, (RIAPAd (RICORS) ) , which is a project (RD21/0009/0010) funded by the Carlos III Institute, the European Regional Development Fund, and the Recovery, Transformation, and Resilience Plan.

Impacto en los Objetivos de Desarrollo Sostenible (ODS)

Análisis de autorías institucional

Compartir

Alcohol-associated liver disease: Natural history, management and novel targeted therapies

Publicado en:Clinical And Molecular Hepatology. 31 - 2025-02-01 31(), DOI: 10.3350/cmh.2024.0709

Autores: Alvarado-Tapias, Edilmar; Pose, Elisa; Gratacos-Gines, Jordi; Clemente-Sanchez, Ana; Lopez-Pelayo, Hugo; Bataller, Ramon

Afiliaciones

Resumen

Alcohol consumption is a leading cause of preventable morbidity and mortality worldwide and the primary cause of advanced liver disease. Alcohol use disorder is a chronic, frequently relapsing condition characterized by persistent alcohol consumption despite its negative consequences. Alcohol-associated liver disease (ALD) encompasses a series of stages, from fatty liver (steatosis) to inflammation (steatohepatitis), fibrosis, and, ultimately, liver cirrhosis and its complications. The development of ALD is complex, involving both genetic and environmental factors, yet the exact mechanisms at play remain unclear. Alcohol-associated hepatitis (AH), a severe form of ALD, presents with sudden jaundice and liver failure. Currently, there are no approved targeted therapies able to interfere in the pathogenesis of ALD to stop the progression of the disease, making alcohol abstinence the most effective way to improve prognosis across all stages of ALD. For patients with advanced ALD who do not respond to medical therapy, liver transplantation is the only option that can improve prognosis. Recently, AH has become an early indication for liver transplantation in non-responders to medical treatment, showing promising results in carefully selected patients. This review provides an update on the epidemiology, natural history, pathogenesis, and current treatments for ALD. A deeper insight into novel targeted therapies investigated for AH focusing on new pathophysiologically-based agents is also discussed, including anti-inflammatory and antioxidative stress drugs, gut-liver axis modulators, and hepatocyte regenerative molecules. (Clin Mol Hepatol 2025;31(Suppl):S112-S133)

Palabras clave